MK256

Overview

MK256 is an orally active, selective CDK8 inhibitor and CDK19/cyclin C inhibitor with IC 50 values of 2.5 nM and 3.3 nM, respectively. MK256 downregulates phosphorylated STAT1 (S727) , STAT5 (S726) , MCL-1 mRNA and CCL2 mRNA . MK256 exhibits anti-tumor activity in acute myeloid leukemia. MK256 can be used for the research of acute myeloid leukemia.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Acute Myeloid Leukemia | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > CCR | Products > Signaling Pathways > CDK | Products > Signaling Pathways > STAT

Product Information

• Catalog No.: HY-183423
• CAS No.: 2271348-04-8
• Molecular Formula: C14H9BrN2O2
• Molecular Weight: 317.14
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source